Novozymes AS

Company Profile

Novozymes AS had its IPO on under the ticker symbol NVZMY.

The company operates in the Basic Materials sector and Specialty Chemicals industry. Novozymes AS has a staff strength of 6,852 employees.

Stock update

Shares of Novozymes AS opened at $44.59 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $44.42 - $44.89, and closed at $44.85.

This is a +1.2% increase from the previous day's closing price.

A total volume of 105,390 shares were traded at the close of the day’s session.

In the last one week, shares of Novozymes AS have increased by +3.44%.

Novozymes AS's Key Ratios

Novozymes AS has a market cap of $12.42 billion, indicating a price to book ratio of 6.1231 and a price to sales ratio of 0.8047.

In the last 12-months Novozymes AS’s revenue was $17.74 billion with a gross profit of $9.59 billion and an EBITDA of $5.63 billion. The EBITDA ratio measures Novozymes AS's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Novozymes AS’s operating margin was 25.03% while its return on assets stood at 10.14% with a return of equity of 26.21%.

In Q2, Novozymes AS’s quarterly earnings growth was a negative -24.8% while revenue growth was a negative 1.6%.

Novozymes AS’s PE and PEG Ratio

Forward PE

29.3255

Trailing PE

25.339

PEG

3.8113

Its diluted EPS in the last 12-months stands at $1.77 per share while it has a forward price to earnings multiple of 29.3255 and a PEG multiple of 3.8113. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novozymes AS’s profitability.

Novozymes AS stock is trading at a EV to sales ratio of 0.8581 and a EV to EBITDA ratio of 3.3157. Its price to sales ratio in the trailing 12-months stood at 0.8047.

Novozymes AS stock pays annual dividends of $0 per share, indicating a yield of 1.9% and a payout ratio of 7.11%.

Balance sheet and cash flow metrics

Total Assets

$28.23 billion

Total Liabilities

$6.84 billion

Operating Cash Flow

$0

Capital Expenditure

$549 million

Dividend Payout Ratio

7.11%

Novozymes AS ended 2024 with $28.23 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $28.23 billion while shareholder equity stood at $13.39 billion.

Novozymes AS ended 2024 with $0 in deferred long-term liabilities, $6.84 billion in other current liabilities, 562000000.00 in common stock, $12.90 billion in retained earnings and $2.00 billion in goodwill. Its cash balance stood at $1.05 billion and cash and short-term investments were $1.11 billion. The company’s total short-term debt was $122,000,000 while long-term debt stood at $0.

Novozymes AS’s total current assets stands at $9.37 billion while long-term investments were $0 and short-term investments were $63.00 million. Its net receivables were $3.65 billion compared to accounts payable of $1.32 billion and inventory worth $3.96 billion.

In 2024, Novozymes AS's operating cash flow was $0 while its capital expenditure stood at $549 million.

Comparatively, Novozymes AS paid $0.07 in dividends in 2024.

Other key metrics

Current Trading Price

$44.85

52-Week High

$60.1616

52-Week Low

$42.87

Analyst Target Price

$

Novozymes AS stock is currently trading at $44.85 per share. It touched a 52-week high of $60.1616 and a 52-week low of $60.1616. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $46.95 and 200-day moving average was $49.7 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 5.5% are held by institutions.